 | • レポートコード：MRC2302C142 • 出版社/出版日：360iResearch / 2023年2月3日 • レポート形態：英語、PDF、238ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に1,372.47百万ドルであった世界の脳腫瘍診断＆治療市場規模が、2022年に1,497.34百万ドルになり、2027年まで年平均9.27%で成長して2,336.84百万ドルに拡大すると予測しています。本レポートは、脳腫瘍診断＆治療の世界市場について調べ、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（診断、治療）分析、治療別（化学治療、免疫治療、放射線治療、外科治療、標的治療）分析、診断別（CTスキャン、EEG、分子生物学的検査、MRI、 PET-CTスキャン）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などを以下の構成でまとめております。また、Amgen Inc.、AstraZeneca PLC、Bayer AG、Bristol-Myers Squibb Co、Carestream Health, Inc.、Eisai Inc.、F. Hoffmann-La Roche Ltd、Fujifilm Corporationなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の脳腫瘍診断＆治療市場規模：種類別 - 脳腫瘍診断の市場規模 - 脳腫瘍治療の市場規模 ・世界の脳腫瘍診断＆治療市場規模：治療別 - 化学治療における市場規模 - 免疫治療における市場規模 - 放射線治療における市場規模 - 外科治療における市場規模 - 標的治療における市場規模 ・世界の脳腫瘍診断＆治療市場規模：診断別 - CTスキャンにおける市場規模 - EEGにおける市場規模 - 分子生物学的検査における市場規模 - MRIにおける市場規模 - PET-CTスキャンにおける市場規模 ・世界の脳腫瘍診断＆治療市場規模：地域別 - 南北アメリカの脳腫瘍診断＆治療市場規模 アメリカの脳腫瘍診断＆治療市場規模 カナダの脳腫瘍診断＆治療市場規模 ブラジルの脳腫瘍診断＆治療市場規模 … - アジア太平洋の脳腫瘍診断＆治療市場規模 日本の脳腫瘍診断＆治療市場規模 中国の脳腫瘍診断＆治療市場規模 インドの脳腫瘍診断＆治療市場規模 韓国の脳腫瘍診断＆治療市場規模 台湾の脳腫瘍診断＆治療市場規模 … - ヨーロッパ/中東/アフリカの脳腫瘍診断＆治療市場規模 イギリスの脳腫瘍診断＆治療市場規模 ドイツの脳腫瘍診断＆治療市場規模 フランスの脳腫瘍診断＆治療市場規模 ロシアの脳腫瘍診断＆治療市場規模 … - その他地域の脳腫瘍診断＆治療市場規模 ・競争状況 ・企業情報 |
The Global Brain Tumor Diagnosis & Therapeutics Market size was estimated at USD 1,372.47 million in 2021 and expected to reach USD 1,497.34 million in 2022, and is projected to grow at a CAGR 9.27% to reach USD 2,336.84 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Brain Tumor Diagnosis & Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Diagnosis and Therapeutics. The Diagnosis is further studied across Cerebral Arteriogram, CT Scan, EEG, Lumbar Puncture, Molecular Testing, MRI, PET-CT Scan, and Tissue Sampling. The Therapeutics is further studied across Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy.
Based on Therapeutics, the market was studied across Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy.
Based on Diagnosis, the market was studied across CT Scan, EEG, Molecular Testing, MRI, and PET-CT Scan.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Brain Tumor Diagnosis & Therapeutics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Brain Tumor Diagnosis & Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Brain Tumor Diagnosis & Therapeutics Market, including Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co, Carestream Health, Inc., Eisai Inc., F. Hoffmann-La Roche Ltd, Fujifilm Corporation, GE Healthcare Inc., GlaxoSmithKline PLC, Hitachi, Ltd., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer, Inc., Philips Healthcare, S&P Global Inc., Shimadzu Corporation, Siemens Healthineers AG, Toshiba Corporation, and Toshiba Medical Systems.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Brain Tumor Diagnosis & Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Brain Tumor Diagnosis & Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Brain Tumor Diagnosis & Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Brain Tumor Diagnosis & Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Brain Tumor Diagnosis & Therapeutics Market?
6. What is the market share of the leading vendors in the Global Brain Tumor Diagnosis & Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Brain Tumor Diagnosis & Therapeutics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of neurological disorders
5.1.1.2. Need for tests detecting the presence of tumors
5.1.1.3. Research activities in the molecular diagnostics
5.1.2. Restraints
5.1.2.1. High cost associated with the diagnosis and treatment
5.1.3. Opportunities
5.1.3.1. Rising healthcare expenditure and the favorable reimbursement policies
5.1.3.2. Growing healthcare awareness about the management and therapies of brain tumor
5.1.3.3. Government initiatives for cancer awareness
5.1.4. Challenges
5.1.4.1. Side effects associated with brain tumor therapeutics
5.2. Cumulative Impact of COVID-19
6. Brain Tumor Diagnosis & Therapeutics Market, by Type
6.1. Introduction
6.2. Diagnosis
6.3.1. Cerebral Arteriogram
6.3.2. CT Scan
6.3.3. EEG
6.3.4. Lumbar Puncture
6.3.5. Molecular Testing
6.3.6. MRI
6.3.7. PET-CT Scan
6.3.8. Tissue Sampling
6.3. Therapeutics
6.4.1. Chemotherapy
6.4.2. Immunotherapy
6.4.3. Radiation Therapy
6.4.4. Surgery
6.4.5. Targeted Therapy
7. Brain Tumor Diagnosis & Therapeutics Market, by Therapeutics
7.1. Introduction
7.2. Chemotherapy
7.3. Immunotherapy
7.4. Radiation Therapy
7.5. Surgery
7.6. Targeted Therapy
8. Brain Tumor Diagnosis & Therapeutics Market, by Diagnosis
8.1. Introduction
8.2. CT Scan
8.3. EEG
8.4. Molecular Testing
8.5. MRI
8.6. PET-CT Scan
9. Americas Brain Tumor Diagnosis & Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Brain Tumor Diagnosis & Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Brain Tumor Diagnosis & Therapeutics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Amgen Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AstraZeneca PLC
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Bayer AG
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Bristol-Myers Squibb Co
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Carestream Health, Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Eisai Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. F. Hoffmann-La Roche Ltd
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Fujifilm Corporation
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. GE Healthcare Inc.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. GlaxoSmithKline PLC
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Hitachi, Ltd.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Johnson & Johnson
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Merck & Co. Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Novartis AG
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Pfizer, Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Philips Healthcare
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. S&P Global Inc.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Shimadzu Corporation
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Siemens Healthineers AG
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Toshiba Corporation
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Toshiba Medical Systems
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing